Editorial

Too much or too little medicine? Overdiagnosis, underdiagnosis, overtreatment and undertreatment in respiratory diseases

Cite as: Dobler CC. Too much or too little medicine? Overdiagnosis, underdiagnosis, overtreatment and undertreatment in respiratory diseases. *Breathe* 2019; 15: 2–3.

At a time when technical possibilities for medical investigations are plentiful and ever expanding, there is growing awareness that more is not always better and that “too much medicine” may be harmful. In recent years, the global Choosing Wisely educational campaign has aimed to bring attention to unnecessary healthcare. Unnecessary healthcare includes overtesting, overdiagnosis and overtreatment [1]. The March issue of *Breathe* aims to challenge us to rethink our clinical practice, to reflect on the evidence, and to identify potential cognitive biases that might influence us to provide “too much” or “too little” medicine [2].

This issue contains a number of articles on the topic of over- and underdiagnosis and over- and undertreatment in respiratory diseases. The pro-con articles on whether asymptomatic patients with moderate-to-severe sleep apnoea should be treated [3, 4] debate a hotly contested topic in sleep medicine and illustrate that evidence is not self-explanatory but needs to be interpreted. Facts are not neutral; they are theory- and value-laden [5, 6], and different people may arrive at varying conclusions based on the same evidence. An article that examines the evidence for screening for sleep disordered breathing in pregnancy, challenges us as clinicians to communicate uncertainty in the evidence to patients [7]. An article giving a global

perspective of over- and underdiagnosis of COPD highlights the seeming paradox that under- and overdiagnosis of COPD coexist in the same setting [8]. Further, the question of whether “aggressive” (surgical) investigation of solitary pulmonary nodules can be justified [9] and the topic of overdiagnosis of pulmonary embolism [10] are explored. Further articles will be published as online exclusives for the March issue. Keep checking the *Breathe* website for newly added content.

We continue the Journal club series that was successfully launched in the December 2018 issue of *Breathe*. I would like to thank Frits Franssen who is the new section editor for the Journal club papers and Cristina Calarasu who is coordinating the commissioning of papers with the early career members of the European Respiratory Society. Topics include: excessive care in the intensive care unit [11]; low-dose CT instead of chest radiography in suspected pneumonia [12]; and procalcitonin-guided antibiotic therapy in lower respiratory tract infections [13]. The lung function corner explores the use of the transfer coefficient of the lung for carbon monoxide and the accessible alveolar volume [14].

The thread topics for upcoming *Breathe* issues are now listed on the website to allow potential contributors to plan well in advance. For 2019 we have planned the following threads: quality of life/living

CrossMark

© ERS 2019

@ERSpublications

The March issue of *Breathe* focuses on overdiagnosis, underdiagnosis, overtreatment and undertreatment in respiratory diseases <http://ow.ly/63OW30ntCeU>

well with a chronic respiratory disease (June), oxygen (September) and biomarkers (December).

I hope that you enjoy this edition of *Breathe* and leave you with the words of Gilbert H. Welch to reflect upon:

“True professionals provide considered advice. And sometimes doing nothing is exactly the right thing to do. The same is true of medicine. Recognize that the doctor who advises no action may be the one who really cares for you.”

Affiliations

Claudia C. Dobler

Dept of Respiratory Medicine, Liverpool Hospital, and University of New South Wales, Sydney, Australia.

Conflict of interest

C.C. Dobler has nothing to disclose.

References

1. Carter SM, Rogers W, Heath I, *et al.* The challenge of overdiagnosis begins with its definition. *BMJ* 2015; 350: h869.
2. Dobler CC, Morrow AS, Kamath CC. Clinicians' cognitive biases: a potential barrier to implementation of evidence-based clinical practice. *BMJ Evid Based Med* 2018; in press [<https://doi.org/10.1136/bmjebm-2018-111074>].
3. Ryan S. Pro: should asymptomatic patients with moderate-to-severe OSA be treated? *Breathe* 2018; 15: 7–10.
4. Vakulin A, Chai-Coetzer CL, McEvoy RD. Con: should asymptomatic patients with moderate-to-severe OSA be treated? *Breathe* 2018; 15: 11–14.
5. Kelly MP, Heath I, Howick J, *et al.* The importance of values in evidence-based medicine. *BMC Med Ethics* 2015; 16: 69.
6. Wieringa S, Engebretsen E, Heggen K, *et al.* Rethinking bias and truth in evidence-based health care. *J Eval Clin Pract* 2018; 24: 930–938.
7. Perkins A, Einion A. Pregnant pause: should we screen for sleep disordered breathing in pregnancy? *Breathe* 2018; 15: 36–44.
8. Ho T, Cusack R, Chaudhary N, *et al.* Under- and over-diagnosis of COPD: a global perspective. *Breathe* 2018; 15: 24–35.
9. Elia S, Loprete S, De Stefano A, *et al.* Does aggressive management of solitary pulmonary nodules pay off? *Breathe* 2018; 15: 15–23.
10. Dobler CC. Overdiagnosis of pulmonary embolism: definition, causes and implications. *Breathe* 2018; 15: 46–53.
11. Okenyi E, Donaldson TM, Collins A, *et al.* Assessing ethical climates in critical care and their impact on patient outcomes. *Breathe* 2018; 15: 84–87.
12. Hoesin FM. Low-dose computed tomography instead of radiography in suspected pneumonia. *Breathe* 2018; 15: 81–83.
13. Mathioudakis AG, Vestbo J. Was the implementation strategy of the ProACT trial adequately proactive? *Breathe* 2018; 15: 77–80.
14. Neder JA, Marillier M, Bernard A-C, *et al.* Transfer coefficient of the lung for carbon monoxide and the accessible alveolar volume: clinically useful if used wisely. *Breathe* 2018; 15: 69–76.